Last reviewed · How we verify

Ketamine infusion

Yale University · FDA-approved active Small molecule Quality 2/100

Ketamine infusion is a Small molecule drug developed by Yale University. It is currently FDA-approved. Also known as: Ketalar, Ketamine hydrochloride, hyperalgesia-blocker.

At a glance

Generic nameKetamine infusion
Also known asKetalar, Ketamine hydrochloride, hyperalgesia-blocker
SponsorYale University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ketamine infusion

What is Ketamine infusion?

Ketamine infusion is a Small molecule drug developed by Yale University.

Who makes Ketamine infusion?

Ketamine infusion is developed and marketed by Yale University (see full Yale University pipeline at /company/yale-university).

Is Ketamine infusion also known as anything else?

Ketamine infusion is also known as Ketalar, Ketamine hydrochloride, hyperalgesia-blocker.

What development phase is Ketamine infusion in?

Ketamine infusion is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing